摘要
放疗联合化疗、内分泌治疗、分子靶向治疗、免疫治疗相较于单一治疗不仅可缩短治疗周期,也可提高局部控制率,延长患者生存期,而联合治疗的安全性仍需进一步明确,以综合评估其可行性。探索放疗联合系统治疗的疗效及安全性将为临床获益患者提供依据。
Compared with single therapy,radiotherapy combined with chemotherapy,endocrine therapy,molecular targeted therapy and immunological therapy can not only shorten the treatment cycle,but also improve the local control rate and prolong the survival of patients.However,the safety of combined therapy still needs to be further clarified to comprehensively evaluate the feasibility.Therefore,exploring the efficacy and safety of radiotherapy combined with systematic therapy will provide evidence for clinical benefits.
作者
李青珊
谢鑫
张楠
刘帅
Li Qingshan;Xie Xin;Zhang Nan;Liu Shuai(School of Clinical Medicine,Weifang Medical University,Weifang 261041,China;School of Graduate,Shandong First Medical University,Jinan 250117,China;Breast Center,Central Hospital Affiliated to Shandong First Medical University,Jinan 250013,China)
出处
《国际肿瘤学杂志》
CAS
2023年第6期362-367,共6页
Journal of International Oncology
基金
山东省自然科学基金(ZR2020QH252)
山东省医学会临床科研资金—齐鲁专项(YXH2022ZX02168)
济南市卫生健康委员会大数据科技计划(2022-YBD-03)
济南市卫生健康委员会科技计划(2020-4-24)
济南市临床医学科技创新计划(202019005)。
关键词
乳腺肿瘤
放射疗法
药物疗法
联合
分子靶向治疗
免疫疗法
Breast neoplasms
Radiotherapy
Drug therapy
combination
Molecular targeted therapy
Immunotherapy
